
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
Pulmovant is a clinical-stage biotechnology company developing innovative therapies for patients suffering from pulmonary diseases. Pulmovants first program, mosliciguat is designed to provide an effective, once-daily, inhaled treatment option for patients with pulmonary hypertension (PH). Mosliciguat is a novel, potential first-in-class, sGC activator with a differentiated mechanism that may have broad applicability across the PH spectrum
Pulmovant operates in the Biotechnology research industry.
Pulmovant's revenue is 11m - 100m
Pulmovant has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.